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INTRODUCTION:  
The discovery of new drugs represents the basis upon 
which the pharmaceutical company and most clinical 
management of diseases rests [1]. However, the rising 
cost of developing a new drug together with tightening 
drug regulatory policies, is mounting pressure on Pharma 
industries to evolve cost-effective ways of bringing new 
drugs to the shelves [2-6;6-8]. For instance, this has led to 
the emergence of virtual screening and other computer-
aided drug design methods [4;9-19]. In virtual screening, 
a rules-based physicochemical filter is used to exclude 
unlikely candidates from the chemical library [12-16]. This 
significantly reduces the cost of synthesizing the 
compounds and performing high through-put assays; it is 
typical to have the library reduced from a million 
compounds to a few hundreds which are then screened 
in wet lab[13]. Apart from virtual methods to drug 
discovery, pharmaceutical companies are also 
increasingly either outsourcing the discovery phase or 
buying off promising projects from smaller institutions 
[20-23]. In the end however and in any case, the success 
of a development project vitally depends on the 
identification of suitable lead compounds that survive the 
discovery pipeline into preclinical trials [22]. The 
continued survival of the pharmaceutical world and most 
of our clinical apparatus depends on the discovery of new 
drugs 1) for the management of incurable diseases 2) to 
confront the resistance development, and 3) to improve 
upon existing chemotherapeutic agents.    
For decades, ethnomedicine has continued to constitute 
a viable source of new leads for drug development [23-
31]. Vincristine from Catharanthus roseus, quinine from 
Cinchona, reserpine from Rauwolfia serpentina, artemisin 
from Artemisia annua, paclitaxel from Taxus brevifolia 
are but few examples of its substantial contribution to 
modern drug use. It was estimated that roughly 80 
percent of existing drugs are either wholly or partly 
derived from plant sources [31]. These phytochemicals 
represent millions of years of evolutionary synthesis, 
which partly explains the chemical complexity that often 
renders them intractable for synthetic chemistry, but that 
also underlies their diverse pharmacological actions 
spectrum [24;32-38].   
The use to which ethnomedicine sources are subjected 
often depends on the quality of effort one is willing to 
invest to arrive at the medicinally useful principles. In the 
prehistory of modern medicine, plants were used in raw 
forms in local formulations relying on crude 
extraction[39]. Developments in pharmacology and 
chemistry in the first half of the 20th century encouraged 
the isolation and synthetic modification of the active 
principles, as well as their pharmacological profiling[40]. 
By functionalizing the isolated active compounds it 
became possible to improve upon the isolate’s 
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pharmacological profile. The resulting optimized 
molecules can then pass through preclinical and clinical 
developments before being licensed for human use after 
sufficient proofs have been demonstrated for its safety 
and efficacy. 
In other words, to make the most of an ethnomedically 
important plant, it is often helpful to have its active 
principles identified, isolated and characterized. While 
most of the world’s developing countries as represented 
by Nigeria are richly endowed with rich flora and 
biodiversity, the local research communities have yet to 
translate this natural endowment into new drugs. In the 
present article we have investigated how factors 
surrounding the conduct of ethnomedicine-based drug 
research in Nigeria help to predict the possibility of 
advancing drug candidates to preclinical trials.  
In modern day science, following the identification of the 
ethnomedicinal importance of a plant material, drug 
discovery efforts usually follow an activity guided 
extraction path beginning from the crude extracts to the 
identification of the most active and safest metabolite. 
Here, plant selection is either based on the widespread 
use in indigenous traditional medicine, or as a part of an 
exploratory research. 
In the simplest sense, once the plant material is collected, 
appropriate extracting solvents especially capable of 
solubilizing a broad range of compounds (e.g. water and 
methanol) are selected to obtain the crude extract. The 
unstated goal of crude extraction is usually to get as 
many and as much present metabolites into the solvent 
medium. The crude extracted is then tested for biological 
activities which may involve testing against batteries of 
physiologic or pathologic model systems. The crude 
extracts typically contain tens and hundreds of different 
chemicals, with activities ranging from beneficial, to toxic, 
to inert. Drug discovery research aims at optimizing the 
beneficial biological properties while eliminating 
toxicities. Subsequent fractionation using 
chromatographic setup (for example) separates the 
components along polarity/solubility line. Structure-
determination tools such as the nuclear magnetic 
resonance (NMR), mass-spectrometry (MS), and x-ray 
crystallography are then employed in determining the 
chemical identity of each fraction. Repeating the 
biological assay at each step helps to track the activity of 
interest from the crude extract, usually with the weakest 
activity, to the pure isolate which is expected to 
demonstrate enhanced activity devoid of pharmacologic 
noise from other compounds present.  
Depending on prevailing factors, the active isolate can 
serve as a new lead. By performing limited modifications 
on the parent compound, a lead series results useful in 
generating structural-activity relationship (SAR). This can 
also permit patent filing. Further lead optimization may 
be required to render the compound of interest more 
drug-like, for example, to improve its oral bioavailability, 
central nervous system penetration and other DMPK 
properties. The resulting drug candidate is then ready for 
preclinical evaluation. 
From the above a model can be designed for quality 
assessment of discovery research. The logic is simple and 
can be captured in this relationship: discovery research 
terminating at the crude extract stage is less likely to 
produce new drug candidates than one that advances to 
the generation of a lead series for SAR.  In this work we 
have generated a logical model to score such implicit 
probabilities encapsulated in the conduct of 
ethnomedicinal research using data from Nigeria. Our 
model additionally suggests ways to improve on 
ethnomedicinal drug discovery research in Nigeria.   
 In the model represented by the scheme labeled “Stages 
in drug discovery from ethnomedicine” (figure 1), the 
discovery process begins with the identification of the 
ethnomedicinal value of a plant material associated with 
a model score (MS) 1, and ends with the achievement of 
at least one drug candidate (MS 8) that can progress into 
preclinical trials. In MS=2, ‘Extracts’, refers to the use of 
crude extraction methods which after subjection to 
further separation as obtained in partitioning with 
solvent systems attains MS 3. At stage 4 the chemical 
identity of the activity principle is determined, which can 
be chemically modified (MS 5) for SAR data. The best 
derivatives constitute the leads which may require 
further modifications (‘Lead optimization’, MS 7) to 
enhance druggability to qualify for preclinical evaluation 
(MS 8).  It follows therefore that the higher the score 
attained, the more advanced the discovery research, and 
the closer the discovery research is in delivering 
candidates for preclinical testing. Higher model scores are 
secondarily an index against which one can estimate 
researchers’ commitment to finding new drugs, or at 
least their success at realizing such commitment. To 
determine the MS for the analyzed research 
investigations we carefully examined the methodologies 
as well as the results. 
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Figure 1: Stages in ethnomedicinal drug discovery research by model score. 
 
MATERIALS AND METHODS: 
Data gathering utilized the PUBMED (www.pubmed.org) 
as target research database which was filtered with two 
search terms- “Nigeria”, and “Plant” applied to all fields. 
While no time limits were employed, the target 
literatures were required to have full articles available. 
The returned articles were downloaded and analyzed 
focusing on the institutional affiliations of researchers, 
the employed research method, and the results. Lastly, a 
list of investigated plant materials was generated and the 
recurrence rates studied. 
RESULTS: 
The performed PUBMED search returned a total of 110 
unique research publications; the present analysis was 
based on 107 found to be relevant to the subject matter 
of ethnomedicinal drug discovery. The examined data 
covered a 14-year period from 2001 through 2014 fifty-
percent of which was published in three years-2011, 
2012, and 2007 (figures 2 and 3). 
 
 
 
Figure 2: Data spread. Shows the distribution of ethnomedicinal drug discovery researches conducted in Nigeria as a function of publication 
year. 
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Figure 3: A representation of publications indicating yearly variations. 
 
Analysis of how the ethnomedicinal researchers 
performed on the MS scale revealed that 80 (~75 %) out 
of the 107 examined data attained MS 2 as the highest 
score, while 19 (~18 %) made it to MS 3 (figure 4). Only 6 
%, however, progressed to MS 4 while two publications 
did not progress beyond MS 1 representing mere 
awareness of ethnomedicinal use. Scores higher than MS 
4 were not observed in the data set. 
 
 
 
Figure 4: The distribution of model scores attained in the analyzed ethnomedicinal research data. 
 
We next examined the influence of foreign collaboration 
(FC) on the attained model scores. We defined foreign 
collaboration institutionally rather than by the 
nationalities of participating researchers. For instance, 
research articles featuring a Nigerian researcher who was 
affiliated with a foreign institution was considered as 
representing a foreign collaboration since foreign 
resources were available for the discovery project. (The 
initial selection criteria for the 107 analyzed data had 
required that at least one Nigerian institution must be 
represented in the research effort.) The number of such 
FCs were analyzed and correlated with the model scores. 
The obtained number of foreign collaboration range from 
FC=0 for no foreign collaboration, to FC=4 representing 
the maximum number of foreign collaborators. To 
suitably compare the relationship between attained 
model score with FC, we normalized the counts by 
dividing with the total number of analyzed investigations 
under each FC grouping. Figure 5, presents the variation 
of model scores with the number of foreign collaborators. 
With no foreign collaborators (FC=0), the analysis peaked 
at MS 2 with normalized research count of 0.8 while only 
0.13 count was recorded for MS 3 and 0.04 for MS 4. 
With FC=1, normalized count increased to 0.14 and 0.07 
for MS 2 and MS 3, respectively. At FC=2, peak for MS 1, 
MS 2, and MS 3 became 0.40, 0.40 and 0.20 respectively. 
With FC=3, the data trend peaked at MS 4. 
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Figure 5: A 3D graph showing the influence of foreign collaborations on the overall quality of ethnomedicinal research as indicated by the 
attained model scores 
 
DISCUSSION 
As already mentioned, data covered a 14-year period 
from 2001 through 2014 (Figure 1) with the fewest 
number of publications recorded in 2001, 2003, and 
2014. Data for 2014 understandably represent an 
incomplete set since data collection took place in the 
early part of the year. The annual growth rate revealed a 
general trend characterized by multiple peaks and 
depressions and ultimately peaking in 2011. The first 
peak was observed in 2005 followed by a trough in 2006. 
A substantial rise was seen in 2007 and 2009 with a 
saddle point in 2008. The next peak, the highest point, 
was recorded in 2011. Oddly, all the peaks were recorded 
in odd-numbered years… The trend of rise in the research 
reveals an erratic growth perhaps suggesting the absence 
of an organized and sustained commitment to drug 
discovery, as might have been suggested by a linear 
pattern of growth. The erratic nature could also reflect 
changing funding structure and the underlying policies 
affecting drug discovery research. Since the 2011 peak in 
2011, research publications into ethnomedicine have 
suffered a sustained downward trend that has persisted 
through the end of 2013. 
80 (~75 %) out of the 107 examined publications attained 
MS 2 as the highest score, while 19 (~18 %) attained MS 3 
(figure 3). Approximately 6 % progressed to MS 4 while 
two publications did not progress beyond MS 1 
representing mere awareness of ethnomedicinal use. 
Scores higher than MS 4 were not obtained in the 
investigated researches. The observed pattern in score 
distribution suggests that a disproportionately large 
amount of resources and attention are focused on crude 
extracts with the studies discontinued at MS 2 for 
different reasons. In the most common instance, 
insufficient funding and the absence of the expected 
activity may cause the termination of a project at MS 2. In 
addition, the pattern may also indicate an underlying 
publications-centric attitude whereby the main aim is to 
turn out publications. And since it is easier, cheaper and 
faster to attain MS 2, more publications can be published 
by strictly sticking to the crude extraction stage in each 
project. This however contrasts with a discovery-centric 
attitude in which the aim is to solve specific scientific 
problems and not merely generating research articles in 
quantities. 
We next examined the influence of foreign collaboration 
(FC) on the attained model scores. We defined foreign 
collaboration institutionally rather than by the 
nationalities of participating researchers. In other words, 
research articles featuring a Nigerian researcher but 
affiliated with an institution outside Nigeria will be 
considered as having a foreign collaboration since foreign 
resources are available to such project. The number of 
such FCs were analyzed and correlated with the model 
scores. It is also worth noting that all 107 research 
articles investigated included at least one Nigerian 
institution, a criterion that qualifies them as Nigerian 
research in the first place. 
The obtained number of foreign collaboration range from 
FC=0 for no foreign collaboration, to FC=4 representing 
the maximum number of foreign collaborators. To 
suitably compare the relationship between attained 
model score with FC, we normalized the counts by 
dividing with the total number of analyzed investigations 
under each FC grouping. Figure 4, presents the variation 
of model scores with the number of foreign collaborators. 
With no foreign collaborators (FC=0), the analysis peaked 
at MS 2 with normalized research count of 0.8 while only 
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0.13 count was recorded for MS 3 and 0.04 for MS 4. As 
the number of foreign collaborators increased, an 
interesting trend began to emerge as the distribution 
began tilting towards higher MS values. With FC=1, 
normalized count increased to 0.14 and 0.07 for MS 2 and 
MS 3, respectively. At FC=2, yet greater tilting towards 
higher MS values resulted with MS 1 reducing to 0.40 
while MS 2 and MS 3 increasing to 0.40 and 0.20 
respectively. At FC=2, the distribution was bimodal with 
peaks at MS 2 and MS 3. The tilting pattern increased and 
eventually peaked at MS 4 with FC=3. (With FC=4, there 
was a reversal in the tilt direction peaking again at MS=2). 
In other words, as foreign collaboration increases 
ethnomedicine-based drug discovery research climbs 
higher the discovery ladder as assessed by the model 
score. This may be as a result of the increased access to 
better experimentation resources such as structure 
determination tools. Collaboration may be an evidence of 
the existence of a stronger commitment to drug 
discovery in which case the attainment of more 
milestones in the discovery path evidenced by the tilt 
pattern of the distribution can be interpreted as a non-
accidental outcome. In any case, based on the data set 
analyzed, foreign collaboration increases the quality of 
ethnomedicinal drug discovery research in Nigeria, and as 
a result the potential to birth a candidate for preclinical 
development.     
Drug discovery research is a highly expensive further 
compounded by the associated high attrition rate. In 
order to understand the major forces affecting 
ethnomedicinal drug discovery research in Nigeria, we 
have analyzed relevant researches published over a 
period of 14 years. Our analysis shows an erratic trend in 
the growth of drug discovery research in spite of the 
increasing health challenges uniquely facing different 
African sub-regions. We suggest this to be a product of 
the absence of adequate research funding backed up by a 
definitive commitment towards ethnomedicinal drug 
discovery research.  
Using a logical model to assess the potential of the 
Nigerian discovery research to deliver new drugs to the 
clinic, our analysis indicates that the widespread 
publication-centric attitude may be an important 
mitigating factor against successful discovery research. 
The leads to the premature termination of promising 
research projects at the level of crude extract where it is 
difficult to objectively capture the complete 
pharmacological essence of the medicinal agent. This 
sharply contrasts with a problem-centric attitude focusing 
on identified disease areas and is strictly committed to 
advancing each project to preclinical and clinical 
developmental phases.  
In certain instances studied, the observed pattern causes 
the repetition of research efforts whereby different 
research groups investigated the same plant and up to 
the same model score stage. 24 plants were observed to 
have been investigated more than once (some up to five 
times): with MS value generally remaining at 2, such 
repeated efforts can hardly be suggested to have any 
direct impact on research quality. Our investigation 
additionally suggests a positive impact of foreign 
collaboration towards the attainment of quality in the 
conduct of ethnomedicinal research in Nigeria. We 
believe this is a result of increased access to research 
equipment and know-how not immediately available in 
Nigeria, or only available at prohibitively high cost to 
individual researchers.  
In conclusion, in order to make good use of the 
abundantly diverse plant resources that richly adorn the 
African clime, it is important that both government and 
private bodies push for a clear-cut commitment towards 
quality ethnomedicinal research. Such commitment 
towards quality should necessarily consider ways of 
encouraging participation in researches that tackle 
specific health problems in the country. One way to 
achieve this is to dedicate grants to specific disease areas 
and having unambiguously defined milestones and 
expected research endpoints. For instance, funded 
postgraduate theses can be beginning to be advertised 
with clear-cut research objective. This has the advantage 
to encourage pragmatism and promote the expenditure 
of research resources in disease areas immediately 
relevant to the country’s needs. This also prevents mere 
academic exercises having no social advantage than the 
conferment of the degree on the researcher. The 
administrators of the limited available funding should 
therefore associate each grant with the solving of specific 
research problems.  
The highly complex nature of drug discovery calls for 
high-level collaboration between different disciplines. In 
particular, collaborations should be encouraged between 
different institutions both local and foreign. Our analysis 
revealed a positive influence of foreign collaboration in 
promoting research quality. By encouraging such 
interactions, for instance via travel grants and by 
requiring foreign collaborations as a precondition for 
granting of certain research funding, the quality of 
ethnomedicinal research in Nigeria can be improved. 
Lastly, to avoid re-inventing the wheel and thus the 
wastage of the available highly limited funding, the 
setting up of a national body for drug discovery research 
is encouraged. Such body will set up a national drug 
discovery data repository for research investigations, the 
model score attained, and recommendations for 
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continuance. Rather than repeating previously conducted 
research, an investigator will only need to inspect the 
repository to avoid research effort duplication and to 
allow the focusing of available resources on advancing 
each project towards preclinical research stage. 
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